Rakovina Therapeutics (TSXV:RKV) Growth Rank : 0 (As of Dec. 16, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Rakovina Therapeutics Growth Rank?

Rakovina Therapeutics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Rakovina Therapeutics Growth Rank Related Terms

Thank you for viewing the detailed overview of Rakovina Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Rakovina Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (TSXV:RKV) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

595 Burrard Street, P.O. Box 49314, Suite 2600, Three Bentall Centre, Vancouver, BC, CAN, V6B 0A5

Website

https://www.rakovinatherapeutics.com

Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some of its products in the pipeline include kt-2000 AI, kt-3000 series. Rakovina gained exclusive use of the Deep Docking AI Platform, enabling it to significantly speed up identifying potential drugs for DNA damage response.

Executives

Jeffrey Bacha	Senior Officer
Mads Daugaard	Senior Officer
Alfredo De Lucrezia	Director, Senior Officer
David Hyman	Senior Officer
John Michael Langlands	Senior Officer

Rakovina Therapeutics Headlines

No Headlines